Novartis Has More Promising Data from Their Phase 3 Gene Therapy Trial with AveXis
AveXis, a Novartis (NVS) company, announced positive interim data from its Phase 3 STR1VE trial of Zolgensma® (onasemnogene abeparvovec-xio (AVXS-101) gene therapy in spinal muscular atrophy (SMA) Type 1.
About Spinal Muscular Atrophy (SMA)
SMA is a severe neuromuscular disease characterized by the loss of motor neurons. The symptoms include progressive muscle weakness and paralysis. SMA is caused by a . . .